ReviewDiscover nano2023
ROS-generating nanoplatforms as selective and tunable therapeutic weapons against cancer.
Review in Discover nano, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 23 citations in OpenAlex.
- Anticancer Activity of Green Synthesized ZnO Nanoparticles fromNanomaterials (Basel, Switzerland) · 2026Article
- Spermine oxidase-DOX conjugates reshape tumor microenvironment via carbonyl stress to potentiate bladder cancer chemotherapy.Materials today. Bio · 2026Article
- Titanium dioxide nanoparticles in oncology: synthesis, application, and challenges.Cell biology and toxicology · 2026Review
- Antimicrobial sonodynamic therapy: Recent advances and challenges in new therapeutic approaches to antimicrobials.Journal of pharmaceutical analysis · 2026Review
- Glucose oxidase-powered nanocatalytic medicine: Rewiring tumor metabolism for multimodal cancer therapy.Materials today. Bio · 2026Review
- The Evolving Landscape of Hepatocellular Carcinoma Therapy: From Conventional Modalities to TME-Responsive Prodrug Design Strategies.Drug design, development and therapy · 2026Review
- Key Tumor Responsive ZIF-8 Nanocarriers for Effective Anti-Cancer Therapeutics.International journal of nanomedicine · 2026Review
- Enhanced Sonodynamic Therapy and Radiotherapy Efficacy: Modified Polyethylene Glycol-Bismuth Trioxide Nanoplatform for Targeted Tumor Treatment.Biomaterials research · 2026Article
- Self-boosting targeted anticancer therapyTheranostics · 2026Article
- Lanthanide Nanotheranostics in Radiotherapy.International journal of molecular sciences · 2025Review
- Targeting the redox-programmed cell death axis in breast cancer: from molecular mechanisms to therapeutic resistance.Cell death discovery · 2025Review
- Self-illuminating liposome-derivedActa pharmaceutica Sinica. B · 2025Article
- Ab Initio Study of Formation Mechanisms and Thermochemical Properties of Reactive Oxygen Species (ROS) in Photocatalytic Processes.International journal of molecular sciences · 2025Article
- Engineering Schottky Junction Nanocatalysts for Enhanced Charge Carrier Separation and Synergistic PDT/PTT/CDT in Bladder Cancer Therapy.ACS biomaterials science & engineering · 2025Review
- Balancing Regeneration and Resistance: Targeting DCLK1 to Mitigate Gastrointestinal Radiation Injury and Oncogenesis.Cancers · 2025Review
- Cerium-doped calcium carbonate microparticles combined with low-intensity ultrasound for efficient sonodynamic therapy in body sculpting.Journal of biological engineering · 2025Article
- Tumor microenvironment regulation by reactive oxygen species-mediated inflammasome activation.Archives of pharmacal research · 2025Review
- Emerging nanoplatforms towards microenvironment-responsive glioma therapy.Medical oncology (Northwood, London, England) · 2025Review
- Article
- An Enzyme-responsive Porphyrin Metal-organic Framework Nanosystem for Targeted and Enhanced Synergistic Cancer Photo-chemo Therapy.Current drug delivery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reactive species refers to a group of chemicals, mainly reactive oxygen species (ROS) and reactive nitrogen species (RNS), that are naturally formed by cells as a byproduct of cell metabolism and regulated by various internal and external factors. Due to their highly chemical reactivity, ROS play a crucial role in physiological and pathological processes which is why studies on ROS regulation for disease treatment show attracted increasing interest. Notably, ROS are now studied as a powerful therapeutic weapon in ROS-regulating therapies such as ROS-based cytotoxic therapies mediated by ROS-increasing agents for cancer treatment. Thanks to the significant progress in nanotechnology, innovative nanoplatforms with ROS-regulating activities have been developed to look for effective ROS-related nanomedicines. In this review, studies on ROS-based cytotoxic therapies against cancer as photodynamic therapy (PDT), sonodynamic therapy (SDT), radiation therapy (RT) and chemodynamic therapy (CDT) are discussed, with a focus on the stimuli-responsive ROS-generating nanoplatforms developed for breaking the current therapeutic limits of ROS-based cytotoxic therapies. Finally, we suppose that our review on this developing field will be valuable for promoting the progress of ROS-based cytotoxic therapies not only in basic research but overall, in translational research and clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.